Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications; Correction
By Health, Drug Administration, Human Services Department, Food · Oct 5, 2026, 11:00 PM CDT
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on May 7, 2026. The document announced the withdrawal of approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of June 8, 2026. The document indicated that FDA was withdrawing approval of ANDA 210285 for dimethyl fumarate delayed-release capsule, 120 milligr
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisNeutral languageThe article uses straightforward, descriptive language without emotive or persuasive wording.
Procedural framingThe piece frames the information around the procedural steps taken by the FDA and the applicant, emphasizing the administrative process.
Context
AI analysisMissing context
The article does not explain why the FDA initially intended to withdraw the 15 ANDAs, which other applicants were affected, or the regulatory criteria that trigger such withdrawals. It also lacks information on any public health or safety implications of the withdrawn approvals.
Important context
The correction indicates that at least one ANDA (210285) remains approved due to a timely request from the applicant, showing that the withdrawal process can be halted by the holder of the ANDA. This highlights the procedural aspect of FDA approvals and withdrawals.
Opinion vs. reporting
AI analysisThe text is purely factual reporting of an FDA correction notice; it contains no opinion or editorial commentary.